论文部分内容阅读
1984年1月至1985年7月,103例卵巢癌进行治疗。属Ⅰ期者11例,Ⅱ期15例,Ⅲ期45例,Ⅳ期7例,复发癌25名;浆液性腺癌70例。患者先行腹式全宫附件及大网切除术,并切除盆、腹腔之肿瘤。残余癌体积的直径超2厘米,是Henckhoff管于腹腔。103患者中49例作肿瘤干细胞分析及CA 125检测,54名为对照组。据肿瘤干细胞分析以选择抗癌药,研究组采用15种不同化疗方案;对照患者用12种。患者经手术及化疗达完全缓解或部分缓解伴有顽固难消的癌块则行再剖腹手术。 本文103例患者中72人生存12至30个月,生存率为69.90％;研究组49例有43例生存,生存率为87.76％,对照组生存29例,占53.70％,二组之生存率比较,P值≤0.113,有差异。对照组25例死亡,平均生存5.5个月,6例研究组死亡者,平均生13.2月。
From January 1984 to July 1985, 103 cases of ovarian cancer were treated. There were 11 cases of stage Ⅰ, 15 cases of stage Ⅱ, 45 cases of stage Ⅲ, 7 cases of stage Ⅳ, 25 cases of recurrent cancer and 70 cases of serous adenocarcinoma. Patients with abdominal first full appendix and omentum resection, and removal of pelvic, abdominal tumor. Residual cancer volume diameter of 2 cm, is Henckhoff tube in the abdominal cavity. Forty-three of 103 patients underwent tumor stem cell analysis and CA 125 detection, and 54 were control subjects. According to cancer stem cell analysis to select anticancer drugs, the study group used 15 different chemotherapy regimens; the control patients used 12. Patients with complete remission by surgery and chemotherapy or partial remission with refractory refractory cancer block was performed laparotomy. In this paper, 72 out of 103 patients survived for 12 to 30 months with a survival rate of 69.90%. In the study group, 43 patients survived with a survival rate of 87.76% in 49 patients and 29 patients (53.70%) in the control group. The survival rates of the two groups Comparison, P value ≤0.113, there are differences. Control group, 25 patients died, the average survival of 5.5 months, 6 patients died in the study group, an average of 13.2 months.